Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Zygote ; 28(1): 24-31, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31603065

RESUMO

This study evaluated the effects of oocyte meiosis inhibitors roscovitine (ROS) and butyrolactone I (BL-I) on in vitro production of bovine embryos. Bovine oocytes were maintained in pre in vitro maturation (pre-IVM) with 25 µM ROS or 100 µM BL-I for 24 h to delay meiosis and for 24 h in in vitro maturation (IVM). Following this treatment, the nuclear maturation index was evaluated. All embryos degenerated following this procedure. In the second set of experiments, oocytes were maintained for 6 or 12 h in pre-IVM with the following three treatments: ROS (25 µM or 12.5 µM), BL-I (100 µM or 50 µM) or a combination of both drugs (6.25 µM ROS and 12.5 µM BL-I). Oocytes were cultivated for 18 or 12 h in IVM. When a meiosis-inducing agent was used during pre-IVM for 24 h, more degenerated oocytes were observed at the end of the IVM period. This effect decreased when the meiotic blocking period was reduced to 6 or 12 h. No significant differences were observed in the blastocyst production rate of oocytes in pre-IVM for 6 h with ROS, BL-I, or ROS + BL-I compared with that of the control group (P > 0.05). However, inhibition of oocytes for 12 h resulted in decreased embryo production compared with that in the controls (P < 0.05). There was no difference in the post-vitrification embryo re-expansion rate between the study groups, showing that the meiotic inhibition for 6 or 12 h did not alter the embryo cryopreservation process.


Assuntos
4-Butirolactona/análogos & derivados , Blastocisto/citologia , Embrião de Mamíferos/citologia , Fertilização in vitro/efeitos dos fármacos , Técnicas de Maturação in Vitro de Oócitos , Meiose , Oócitos/citologia , Roscovitina/farmacologia , 4-Butirolactona/farmacologia , Animais , Blastocisto/efeitos dos fármacos , Bovinos , Embrião de Mamíferos/efeitos dos fármacos , Feminino , Oócitos/efeitos dos fármacos , Inibidores de Proteínas Quinases/farmacologia
2.
Zygote ; 24(2): 161-71, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25707683

RESUMO

The inhibition of nuclear maturation allows time for the oocyte to accumulate molecules that are important for embryonic development. Thus, the objective of this work was to evaluate the effect of blocking oocyte meiosis with the addition of forskolin, an efficient inhibitor of nuclear maturation, in in vitro maturation (IVM) medium. Forskolin was added to the IVM medium for 6 h at concentrations of 0.1 mM, 0.05 mM or 0.025 mM, then the oocytes were allowed to mature in drug-free medium for 18 h. The oocytes were assessed for the stage of nuclear maturation, the activity and distribution of mitochondria, oocyte ultrastructure, the number of viable cells and the apoptosis rate. After forskolin treatment, the oocytes were fertilized in vitro and cultured for 7 days. On day 7, the blastocyst rate, the ultrastructure, the number of intact cells and the apoptosis rate of the blastocysts were measured. No differences were observed for the stage of nuclear maturation of the oocyte, the mitochondrial activity and distribution, the blastocyst rate or total number of intact cells. However, a higher rate of apoptosis was observed in the blastocysts produced from oocytes blocked for 6 h with the higher concentration of forskolin (P < 0.05). We conclude that all the experimental groups reached the MII stage after the addition of forskolin and that the highest concentration of forskolin caused cellular degeneration without harming embryo production on the 7th day.


Assuntos
Blastocisto/efeitos dos fármacos , Colforsina/farmacologia , Fertilização in vitro/métodos , Oócitos/efeitos dos fármacos , Animais , Blastocisto/citologia , Bovinos , Células Cultivadas , Desenvolvimento Embrionário/efeitos dos fármacos , Feminino , Fertilização in vitro/veterinária , Masculino , Meiose/efeitos dos fármacos , Oócitos/citologia , Fatores de Tempo , Vasodilatadores/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA